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Intravenous (i.v.) hypertonic mannitol, the first pharmacologic
agent to be used for prophylaxis against acute renal failure (ARF)
[1], was introduced by Homer Smith in 1940 to estimate glomer-
ular filtration rate (GFR) in humans and dogs [21. Smith noted the
osmotic diuretic effect of mannitol. This was followed by Selkurt
in 1945 who showed that mannitol ameliorated ischemic ARF in
the dog [3]. In the half century that elapsed since then, mannitol
prophylaxis against ARF in humans was used widely but not
universally by the nephrology community.
The purpose of the present communication is to review the
effect of mannitol on normal kidney function as well as its clinical
therapeutic potential in the prevention of ARF and protection of
skeletal muscle function following crush injury.
Osmotic diuretics are freely filterable, low molecular weight
substances that due to their limited reabsorption and small size
create an osmotic force in the tubular fluid sufficient to retard the
reabsorption of fluids and solutes (notably NaCI) along the
nephron. Thus, osmotic diuresis results in urinary loss of water,
sodium, potassium and divalent cations.
Mannitol, a six-carbon nonmetabolizable polyacohol with a
molecular weight of 182, is perhaps the oldest and most widely
employed osmotic diuretic agent [21. Numerous studies in exper-
imental animals and humans, under both physiologic and patho-
physiologic conditions, have contributed significantly to our un-
derstanding of its renal and extrarenal actions. A compound with
similar effects is sorhitol. Glucose may likewise act as an "endog-
enous" osmotic diuretic agent when present at sufficiently high
concentrations in the glomerular filtrate, to exceed the reabsorp-
tion capacity of the proximal nephron. Other partially or poorly
reabsorbable agents, such as urea and sulfates, were included in
the past in the category of osmotic diuretics, because, when
present in high concentrations in plasma, they may increase urine
flow rate, in part by a mechanism similar to that of mannitol [4].
Beyond its action as a diuretic agent, mannitol has been used by
many renal physiologists, over the past five decades, as an
important tool in the study of the mechanisms of salt and water
transport at the tubular and cellular level. As a physiologic probe,
mannitol has contributed to our understanding of these transport
processes.
Key words: mannitol, crush injury, acute renal failure, diuretics.
Reccivcd for publication February 13, 1997
and in revised form May 9, 1997
Accepted for publication May 12, 1997
© 1997 by the International Society of Nephrology
The introduction of mannitol for prophylaxis against postoper-
ative ARF following cardiovascular surgery [5, 6] was associated
with a dramatic decline in the occurrence of such ARF. Further-
more, mannitol clearly protects renal graft function during ca-
daver kidney transplantation [7, 8]. In addition, mannitol as an
adjunct is useful for the prevention of myoglohinurie ARF in
humans [91. Our experience in the salvage of lives and limbs in
victims of crush injury following mass disasters suggests that
mannitol has also beneficial extrarenal effects [9].
Finally, in addition to being a hyperosmotic agent, mannitol has
been shown also to be an effective scavenger of free hydroxyl
radicals in many biologic systems at least extracellularly [10, 111
since mannitol is an impermeant solute.
RENAL EFFECTS OF MANNITOL
Intravenous administration of mannitol results in a brisk diuret-
ic/natriuretic response. Depending on the dose adminstered,
urine flow in humans may reach 20% to 30% of the filtered load
of water, and up to 10% to 15% of the filtered Na may be
excreted during the height of the diuresis [1 In the dog, even
larger inhibition of water and salt reabsorption has been reported,
with massive doses of mannitol injected [12].
Concomitant with the diuresis and natriuresis produced by
mannitol, the excretion of other ions such as Ca2, Mg2,
phosphate and bicarbonate is also increased. Urinary concerntra-
tion and dilution ability is severely impaired, and urine osmolality
tends to approach isotonicity during peak diuresis [13]. Many
studies in the past have focused on the tubular effects of mannitol
as the dominant mechanism by which the diuretic effect of the
drug is achieved. However, in addition to its actions on salt and
water reabsorption along the nephron, mannitol has important
glomerular, systemic and renal hcmodyanmic effects, which, in
turn, may influence and modulate its tubular actions. Further-
more, since injeced mannitol is confined primarily to the extra-
cellular fluid compartment, the increase in osmotic pressure
induced by mannitol results in water shifts from the intracellular
compartment. Such redistribution of fluid may lead to extracellu-
lar volume expansion, as well as a decrease in plasma oncotic
pressure, and blood viscosity and hematocrit values, which will
further increase renal perfusion. Finally, the increase in extracel-
lular fluid volume may activate endogenous natriuretic agents,
and suppress antinatriuretic hormone systems, thereby contribut-
ing to the diuretic/natriuretic effect of mannitol. The major renal
actions of mannitol are as follows:
(1.) Increase in cortical and medullary blood flow due to a
decrease in RVR
886
Better et al: Clinical use of mannitol 887
(2.) Increase in GFR during renal hypoperfusion. Variable
effects on GFR in kidneys with normal function.
(3.) Prominent diuretic/natriuretic action due to inhibition of
tubular reabsorption of water and salt.
(4.) Increase in urinary excretion of K, Ca2, Mg2, phos-
phate and bicarbonate.
(5.) Dissipation of medullary hypertonicity. Impairment of
urinary concentration and dilution capacity.
(6.) Increase in renal interstitial pressure and in intratubular
pressure.
(7.) Indirect actions on the kidney through an increase in ECF
volume, dilution of plasma proteins and decrease in blood viscos-
ity, release of prostaglandins and ANF, and inhibition of renin
angiotensin system
Effects of mannitol on renal hemodynamics
In most experimental settings, infusion of hypertonic mannitol
increases renal blood flow (RBF), apparently by reducing renal
vascular resistance (RVR) [14—161. The increase in total RBF is
reflected by a concomitant increase in both cortical blood flow and
medullary perfusion [17, 18]. Moreover, the effect of mannitol on
RBF is observed under normotensive conditions [15], as well as in
animals made hypotensive by bleeding, and in the hypoperfused
rat kidney, an experimental model of "prerenal failure" [19]. The
restoration of RBF and GFR following mannitol infusion in the
hypoperfused kidney [3, 19, 20] is the rationale for its use in the
treatment and prophylaxis against impending ARF.
On the other hand, massive doses of mannitol may cause a
paradoxical constriction of the main renal artery [21] with an
increase in RVR, and decrease renal perfusion [22]. This phe-
nomenon may be due to constriction of the efferent arteriole in
response to the high concerntration of mannitol. The mechanism
by which mannitol exerts its effects on RBF is not thoroughly
understood. In the in situ perfused dog kidney, Goldberg and
Lilienfield [23] demonstrated that systemic infusion of hypertonic
mannitol resulted in a marked decrease in RVR. A similar
decrease was produced by direct infusion of mannitol into the
renal artery, and also by dextran and saline infusion, but not
during infusion of whole blood. These decreases in vascular
resistance correlated with diminshed hematocrits of the perfusion
fluids, suggesting that the diminished viscosity of blood following
mannitol infusion could contribute to the increase in RBF [23].
Earlier observations [14] have also suggested a similar linkage
between the decrease in the hematoerit and RVR. However,
assuming that blood at physiologic rates of flow has a stable
viscosity, the observed changes in hematocrit were not sufficient to
explain the effects of mannitol on RVR. Therefore, additional
mechanisms, unrelated to changes in blood viscosity, must be
invoked. It is of interest that renal denervation and autonomic
ganglioplegia did not influence the effects of hyperosmotic man-
nitol on RVR [23]. This suggests that suppression of enhanced
sympathetic activity is probably not involved in the mechanism of
action of mannitol on RVR.
It is likewise possible that mannitol may exert its renal vasodi-
latory action indirectly, that is, by releasing other vasoactive
agents. Thus, in the hypoperfused rat kidney, prior treatment with
cyclooxygenase inhibitors markedly attenuated the renal vasodi-
latory effect of mannitol [20]. During hypoperfusion, the intrare-
nal infusion of prostacyclin (P012), but not of prostaglendin E2
(PGE2), resulted in an increase in RBF, and restored the renal
vasodilatory response to mannitol. Interestingly, the renal vascu-
lar response to mannitol was not altered by pretreatment with an
angiotensin-converting enzyme inhibitor, inhibitors of the kinin-
kallikrein system or inhibitors of thromboxane synthesis. These
findings suggest that in the ischemic hypoperfused rat kidney the
vasodilatory response to mannitol administration is mediated
largely by increased P012 synthesis [20]. An additional indirect
mechanism by which mannitol may exert its action on renal
hemodynamics is by augmenting atrial natriuretic factor (ANF)
release. It has been recently demonstrated that mannitol infusion
may increase plasma levels of this vasodilatory natriuretic hor-
mone, apparently due to the intravascular volume expansion
induced by mannitol or directly by the effect of hyperosmotic
perfusion [24]. It remains to be established if, and to what extent,
ANF may mediate the natriuretic and vasodilatory response to
mannitol.
The increased renal perfusion following mannitol is associated
with a proportional increase in both cortical and medullary blood
flow [16—18]. The fact that medullary blood flow is significantly
increased by hypertonic mannitol may contribute to the medullaiy
"washout phenomenon," and is consistent with the marked dissi-
pation of medullary hypertonicity observed during osmotic diure-
sis [23, 25]. This, in turn, could contribute to the mechanism by
which mannitol inhibits salt and water reabsorption in the loop of
Henle, and also explains, in part, the obliteration of urinary
concentration and dilution capacities induced by osmotic diuresis.
Influence of inannitol on glomerular filtration rate
In contrast to the increase in RBF observed during mannitol
diuresis, reports of the changes in GFR are conflicting. In the dog
kidney, micropuncture studies have indicated a significant de-
crease in single nephron glomerular filtration rate (SNGFR)
associated with a similar fall in whole kidney GFR [26].
In contrast, in the human and in the rat, whole kidney GFR is
either unchanged or slightly increased during mannitol infusion
[23, 27, 28]. In addition to species variations, the change in GFR
in response to mannitol depends largely on the baseline condition.
Thus, in the hypoperfused kidney, including the dog kidney,
infusion of mannitol tends to restore GFR towards normal levels
[3, 19]. It appears, therefore, that several factors may influence the
GFR response to mannitol administration.
The influence of mannitol on glomerular determinants in the
rat kidney was evaluated by micropuncture methodology [27].
Mannitol had a consistent and profound effect upon the SNGFR
in the hydropenic rat, increasing the filtration rate by 31%. This
increment was due to both increase in single nephron plasma flow
and a decrease in afferent arterial oncotic pressure secondary to
dilution of plasma protein. More than half of the alteration in
SNGFR was due to a decrease in afferent oncotic pressure,
suggesting that dilution of plasma protein has a major effect on
SNGFR [27].
In a more recent study [18] it was demonstrated that superficial
and deep nephron filtration rates may be influenced differentially
during mannitol infusion. In the latter study, whole kidney GFR
remained unchanged during mannitol diuresis. However, SNGFR
of superficial nephrons increased by 31% in response to mannitol
infusion, whereas deep nephron SNGFR fell by approximately
40% [18]. The redistribution of GFR from juxtamedullary to
superficial nephroris may be related to a decline in efferent
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resistance of deep nephrons secondary to the decrease in viscosity
of the blood in the vasa recta as well as in diminution of
glomerular membrane permeability [18].
The effects of manriitol on GFR under circumstances of
reduced renal perfusion are of major interest, both in pathophys-
iologic and clinical implications. Since its introduction by Selkurt
in 1945 [3], mannitol has been widely used to prevent and treat
experimental and clinical ARF because of its ability to maintain
glomerular filtration during renal hypoperfusion. Morris et al [19]
reported that in the hypoperfused rat kidney, an experimental
model of prerenal failure, prior infusion of mannitol maintained
glomerular filtration, which otherwise would stop when renal
arterial pressure was reduced to 40 mm Hg. Moreover, when
given after hypoperfusion has been induced, mannitol will re-
establish glomerular filtration that has already stopped [19].
Under the same conditions, infusion of equal or greater volumes
of isotonic saline did not maintain or re-establish GFR, suggesting
that the effect of mannitol is probably independent of the
influence of volume expansion per Se, or the dilution of plasma
protein. The authors proposed that mannitol exerted this effect by
dilating the afferent arteriole, probably due to suppression of
renin release and the intrarenal formation of angiotensin II [28,
29].
A possible role for mannitol in maintaining GFR during renal
ischemia, by reducing endothelial cell swelling, was originally
suggested by Flores et al [30]. These authors proposed that the
failure of the blood flow to return to the kidney following
transient ischemia, the so-called no reflow phenomenon, was due
to swollen endothelial cells limiting the available vascular space.
They further demonstrated that the "no reflow" and subsequent
renal dysfunction were corrected by hypertonic mannitol, but not
by equivalent expansion with isotonic saline or isotonic mannitol,
indicating that the osmotic effects were primary [301. More
recently, Mason et [31] demonstrated by morphometric analysis
that renal ischemia resulted in swelling of proximal tubular cells
and thick ascending limb cells. This altered geometry led to
depletion of the interstitial and vascular space in the cortex,
resulting in vascular congestion, which, in turn, was responsible
for the poor perfusion and impaired renal function. The injection
of mannitol into the renal artery prior to ischemia reduced cell
swelling and vascular congestion, and eliminated the occlusion of
the thick ascending limb, thereby preventing the impairment in
renal function [31].
The finding that mannitol might maintain glomerular filtration
in the hypoperfused kidney is consistent with earlier observations
indicating that mannitol prevented the decrease in GFR after
hypotensive episodes [15, 32]. Similarly, in patients undergoing
abdominal aortic aneurysmectomy [5] and open heart surgery
[33], and in severely injured patients [34], mannitol has been
shown to increase GFR.
It is of interest that, despite the striking protective effects of
mannitol on GFR under circumstances of low renal perfusion
pressure, GFR remains unchanged or even decreased in intact
animals and normal volunteers infused with mannitol [15, 16, 35,
36]. These findings may imply that the beneficial actions of
mannitol observed during renal hypoperfusion are probably me-
diated by antagonizing systems that are activated when renal
perfusion is severely compromised.
Influence of mannitol on tubular salt and water reabsorption
The entire tubular length from the proximal tubule [28, 36] to
the loop of Hence [18, 26, 37] to the collecting duct [18, 381
participate in the natriuretic and diuretic action of mannitol. The
following are the current views on the action of mannitol along the
various tubular segments.
Action of mannitol in the proximal nephron. Mannitol has no
direct inhibitory effect on Na transport in the proximal nephron.
Rather, mannitol indirectly influences Na transport by virtue of
its effect on water reabsoption. The obligatory presence of man-
nitol in the tubular fluid retards water reabsorption along this
nephron segment. As a result, the concentration of Na in the
tubular fluid decreases, and because cellular water content falls
the concentration gradient against which Na must be trans-
ported increases [4]. This in turn would diminish outward Na
transport, and at the same time increase the passive backflux of
Na into the tubule, leading consequently to a progressive
reduction in net Na reabsorption. When tubular Na1 concen-
tration reaches 30 to 40 mmol/liter below that in peritubular fluid.
A limiting gradient for Na transport is reached, and net Na
reabsorption stops [18, 26, 36, 37].
Action of mannitol in the loop of Henle. Seely and Dirks [26]
were the first to indicate the importance of the loop of Henle as
a predominant site of the diminished salt and water reabsorption
during osmotic diuresis. Their findings were verified by others [18,
371.
It is likely that the inhibition of Na reabsorption in the loop of
Henle is restricted mainly to the thin ascending limb [4]. In
contrast, salt reabsorption in the thick ascending limb occurs
mainly by a secondary active mechanism mediated by an Na
2CL K* carrier [39]. Since salt reabsorption in this segment is
load dependent, the increased delivery of salt and water during
osmotic diuresis may actually enhance Na reabsorption. This is
supported by the observation that free water reabsorption is
progressively increased in man during osmotic diuresis [401.
Additionally, in the rat [18] but not in the dog [26] there is a
significant reabsorption of salt and water between late proximal
and early distal tubular sites of superficial nephrons.
In summary, the effects of mannitol diuresis on loop function
involve a marked reduction in water and salt reabsorption in the
descending and thin ascending limbs, respectively, followed by
incomplete recapture of the increased Na tubular load in the
thick ascending limb [4]. The magnitude of these effects may
depend on the fitered load of mannitol as well as on species
differences.
Action of mannitol on the distal tubule and collecting duct.
During osmotic diuresis the delivery of salt and water to the distal
tubule and collecting duct is markedly increased. However, the
final segments of the nephron fail to recapture the increased
delivered loads of salt and water. Apparently, the high distal flow
rate overwhelms the capacity for Na reabsorption in the collect-
ing duct [4].
The function of the collecting duct during osmotic diuresis was
studied by the microcatheterization and micropuncture tech-
niques [18, 38]. Both studies demonstrated that the reabsorption
of delivered salt and water was diminished in the collecting duct
during mannitol diuresis. Moreover, at the medullary collecting
duct mannitol had direct inhibitory influence on sodium reabsorp-
tion above and beyond its osmotic natriuretic properties [38].
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Fig. 1. Mechanism of myoglobinuric ARE
following crush injury to skeletal muscle.
Mechanical pressure and the resulting
membrane stretch cause sarcolemmal leak. As a
result extracellular water, sodium and calcium
flood the myocytic cytosol leading to muscular
swelling, hypovolemia and hypocalcemia. The
stretched sarcolemma leaks into the
extracellular fluid potassium and the
nephrotoxic metabolites myoglobin, purines
(precursors for urate) and phosphate [831.
Mannitol treatment (not shown in the figure)
may decompress the swollen muscle, thus
conceivably relieving sarcolemmal stretch and
restoring its impermeability. By such muscular
action and by increasing urinary elimination of
nephrotoxic muscular metabolites, mannitol
could reduce their pool in the extra cellular
fluid and their burden on the kidney.
Action of mannitol on the transport of ions other than sodium.
Mannitol may increase the urinary excretion of K, Ca2, Mg2
and of phosphate [4, 28, 37, 41—44] parallel to its natriuretic
effects.
Urinary concentration and dilution during mannitol infusion.
Osmotic diuresis as in the case of hypertonic mannitol tends to
abolish the ability to concentrate or to dilate the urine [4, 46, 47].
This osmotic interference with urinary concentration is due in part
to medullary washout and loss of medullary hypertonicity [13, 15].
Miscellaneous effects of mannitol. In addition to the direct renal
tubular, glomerular and hemodynamic effects of mannitol, this
agent may influence renal function indirectly by an effect on other
endocrine or local systems. As pointed out in earlier sections, the
effects of hypertonic mannitol on the release of ANF [24] and
vasodilatory prostaglandins [201 on the one hand, combined with
the suppression of the renin-angiotensin system [48, 49], may be
important factors in determining the diuretic/natriurctic actions of
mannitol. Moreover, infusion of hypertonic mannitol may signif-
icantly affect local pressures within the kidney, which may second-
arily influence tubular reabsorption of salt and water. Thus, direct
measurements of renal interstitial pressure by chronically im-
planted capsules in dog kidney have clearly demonstrated a
marked increase during mannitol infusion [49]. Evidently, the
tubular lumen is not compressed by the increased interstitial
pressure, since intratuhular hydrostatic pressure is also markedly
increased during mannitol infusion [501. Tn fact, direct recordings
of hydrostatic pressures have demonstrated a widening of the
pressure gradients between the intratubular pressure in the
proximal nephron and the adjacent peritubular capillaries [501.
The increased luminal hydrostatic pressure following mannitol
infusion may assist in keeping the patency of the tubular lumen,
and prevent its occlusion during ischemic and toxic insults to the
kidney.
Beneficial extrarenal effects of hypertonic mannitol
Due to its hyperosmotic properties, mannitol may affect other
systems in addition to the kidney. Some of these extrarenal effects,
such as the actions on the central nervous system, the muscles and
the cardiovascular system, are of major clinical importance. The
following section will briefly summarize a few aspects of these
extrarenal effects, some of which are based on our personal
experience.
By mobilizing and redistributing fluid from edematous organs
and tissues, mannitol may improve their function while at the
same time expand the depleted intravascular space in human
trauma casualties [9]. Studies in our laboratory have shown that
mannitol may facilitate decompression of experimental compart-
ment syndrome in the dog [51]. The decompressive effect of
mannitol was presumbly due to its osmotic activity, which tended
to augment fluid removal from the interstitium of the injured
muscle. More recently, we have shown that hypertonic mannitol
enhances recovery of injured muscle in rats with experimental
crush injury induced by applying mechanical pressure on the hind
limb [52]. Hypertonic mannitol caused a significant increase in
twitch amplitude following direct electrical stimulation of the
crushed muscle. Moreover, the effects of mannitol on the recovery
from crush injury was augmented by hyperbaric oxygen treatment.
Others have shown that hyperbaric oxygen is useful in the
management of experimental compartment syndrome in the dog
[531. Taken together, these studies in experimental crush syn-
drome suggest that the combination of intravenous hypertonic
mannitol and hyperbaric oxygen may, in the future, be an impor-
tant adjunct in the treatment of some forms of crush injury in
humans. Since mannitol decompressed post-traumatic turgid
edematous muscles, it is reasonable to assume that such decrease
in sareolemmal stretch reduces the leak of muscule myoglobin
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orate and phosphate (Fig. 1). Thus, mannitol would reduce the
load on the kidney of these nephrotoxic agents and therefore
protect the kidney during rhabdomyolysis. Mannitol appears to be
useful in exertional compartment syndrome in humans (Fig. 2)
(NOTE ADDED IN PROOF).
Fasciotomy for the treatment of the compartment syndrome
following crush injury carries a definite risk to life or limb [9]. A
trial of i.v. mannitol may afford means of non-surgical decompres-
sion in the compartment syndrome and at least buy precious time
in the setting of mass disaster where operating theaters are busy
and scarce. When mannitol is not effective within an hour, then
fasciotomy is indicated as a last resort to decompress intracom-
partmcntal "hypertension."
Finally, when applied in a dosage of less than 200 g/day
mannitol has been used safely and widely for several decades to
relieve cerebral edema and to treat increased intracranial pres-
sure in humans. Intravenous hypertonic mannitol reduces intra-
cranial presure and is also known to cause a definite increase in
cerebral blood flow [54, 551. An attempt was made in our hospital
to correlate the decompressive effect of mannitol with central
nervous system function in human victims of head trauma (Fig. 3)
(M. Feinsod, unpublished observations). Thus, within 30 minutes
the decompressive action of mannitol was followed by correction
of the pathologic prolongation of trigeminal evoked potentials. It
is likely that this normalization of evoked potentials was due to
amelioration of brain edema and the decrease in intracranial
pressure. However, an incidental improvement in cerebral circu-
lation could also have contributed to the observed normalization
of measured brain electrical activity.
Fig. 2. Compartmental decompression with
mannitol in a patient with post.exertional
rhabdomyolysis. A 19-year-old army recruit
from an elite unit was hospitalized with
exertional rhabdomyolysis and heat stroke
following a 60 km strenuous march in which he
carried heavy equipment. His initial treatment
did not include mannitol. On the seventh day
after his admission to the hospital, his entire
right lower limb became extremely painful,
swollen, and hard to palpation. He also
developed right sided drop foot. Intravenous
mannitol therapy resulted in the disappearance
of the pain within hours. The limb became
softer to palpation and its circumference was
reduced. The late clinical course was
uneventful, and normal motor function of the
right foot returned within weeks. Several
months after the event, the solider recuperated
completely and returned to his unit and full
physical activity. Thus, the use of mannitol in
this patient preempted the necessity to perform
fasciotomy, which is the "standard" treatment
for this complication. Had fasciotomy been
performed it is doubtful whether he could have
been able to return to his demanding elite unit.
In our experience, fasciotomy for compartment
syndrome associated with post-traumatic
rhabdomyolysis carries great risk to life and
limb [9]. Symbols are: (—I—) thigh; (——) calf.
(NOTE ADDED IN PROOF).
Effects of mannitol on the cardiovascular system
The influence of mannitol in expanding extracellular and
intravascular volume and improving circulatory function was
alluded to in previous sections. The beneficial effect of mannitol
on the circulation is due to its ability to increase venous return and
cardiac preload, thus stabilizing arterial pressure and organ
perfusion. However, in addition, mannitol has a direct positive
inotropic effect on the heart as shown in the isolated working
heart model [56, 57]. Such an effect of hypertonic solution in
improving myocardial contractility may be due to the increase in
intracellular calcium concentration in the myocytes exposed to
hyperosmolarity [57].
Finally, mannitol has been shown to exert favorable effects on
myocardial edema and infarct size in experimental models of
myocardial infarction and reperfusion. Thus, intracoronary per-
fusion with hyperosmotic mannitol significantly reduced the early
myocardial edema and infarct size following coronary occlusion
and reperfusion [58]. In another study, mannitol-treated hearts
demonstrated improved postischemic left ventricular function,
greater coronary blood flow and improved structural preservation
compared with hearts reperfused with isoosmotic solutions [591. It
was postulated that early treatment with mannitol during post-
ischemic reflow prevented cell swelling, therby maintaining cell
voulume and enhancing myocardial viability. However, other
mechnisms, not related directly to the osmotic properties of
mannitol, such as its action as a potent hydroxyl free radical,
scavengers may also be involved in protecting the ischemic
myocardium [III. However, mannitol does not enter cells and
19 year old soldier from elite unit,
admitted following a 60 km
march on 28/10/95, with:
Heat stroke (42°C)
Seizures
Hyponatremia (123 mEq/liter)
Rhabdomyolysis (CPK 13,000)
Acute renal failure
(creatinine 141 llmol/liter)
Hypokalemia (3.4 mEq!liter)
Hypophosphatemia
Mannitol
25 g
drop foot
49
47
: 45
43
41
39
37
35
C)
CD
CD_0
C) 0
I I1 2 3 4 5 6 7 8 9 10 11 12 13
Day of hospitalization
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2.0 4.9 Initial recording
ICP-38 mm Hg
J
1 m8
1.7 3.5 Administration of
mannitol
1.6 3.1
1.3 2.7 Finalrecording
ICP-20 mm Hg
2.5 isV
Fig. 3. Decompression of cerebral edema with
mannitol. In a patient with post-traumatic
cerebral edema, the effect of i.v. hypertonic
mannitol infusion on intracranial pressure was
measured by direct manometry (intra-cerbral
pressure, ICP). Trigeminal evoked potentials(TEP) were also monitored. The upper curve
taken during increased intracranial pressure
shows decreased amplitude and slowing of the
TEP wave pattern. The lower panels show
progressive normalization of TEP following
cerebral decompression induced by mannitol
(Prof. M. Feinsod, Chief of Neurosurgery,
Rambam Hospital, Haifa, personal
communication, 1994) [85].
it is therefore not clear how it exerts intracellular scavenging
activity.
Clinical use of mannitol
Ext ra renal applications of mannitol. Mannitol is used in the
prophylaxis and treatment of acute renal failure, for the reduction
of pressure and volume of the cerebrospinal fluid and in ophthal-
mology for short-term reduction of intraocular pressure and
vitreous volume. Some authors consider mannitol to be the most
effective drug for reducing intracranial pressure associated with
Reye's syndrome [60]. It is also indicated as an urinary bladder
irrigant during transurethral prostate resection or bladder surgery
to prevent hemolysis. In hemodialysis, mannitol infusion can be
helpful in correcting cramps and hypotension associated with
ultrafiltration. Cerebral edema and ophthalmoplegia due to dia-
betic ketoacidosis may be reversed by prompt therapy with
mannitol [61]. Furthermore, mannitol can be used to enhance the
excretion of drugs in intoxications (such as with barbiturate,
bromide, or aspirin) [62]. The combination of mannitol and
normal saline infusion has been used safely and effectively to treat
the cerebral edema and hyponatremia associated with water
intoxications in infants and children [63].
Phar,nacokinetics. After oral administration approximately 20%
of mannitol is absorbed [641. Following intravenous administra-
tion mannitol is rapidly distributed primarily in the extracellular
space [65, 66] and excreted unchanged in the urine, undergoing no
metabolism [60]. The onset of diuresis or decrease in intracranial
pressure occurs within 15 to 30 minutes after i.v. administration
[64, 67]. The drug does not cross the blood brain barrier, its
volume of distribution is 0.471/kg [68], and its half-life 70 to 100
minutes [60].
Dosage. To treat oliguria 50 to 200 g mannitol may be used
intravenously as a 15% to 20% solution over 24 hours. To reduce
intracranial or intraocular pressure the usual dose is 1.5 to 2 g/kg
intravenously over 30 to 60 minutes as a 20% solution. When used
to enhance the excretion of toxins the total dose should not
exceed 200 g/day. In pediatric patients (17 years of age and
younger) the maximum recommended dose is 2 g/kg [69]. Anuric
patients should not routinely receive mannitol. However, a small
single test dose of 12.5 g of mannitol may be given in the hope of
starting diuresis.
USE OF MANNITOL FOR THE PREVENTION OF ACUTE
RENAL FAILURE
One of the most common forms of ischemic ARF, and certainly
the best monitored in clinical practice, is associated with kidney
transplantation, particularly from cadaver donors. Well controlled
prospective studies have clearly shown that mannitol has a distinct
value in protecting graft function [7, 8, 70]. Furthermore, 20 years
of experience in the improvement of ex-vivo kidney preservation
solutions indicate that the addition of mannitol, or otherwise
insuring hypertonicity of the perfusate (320 to 350 mOsm/kg) is
critical to the efficacy of prevention of post-transplant ARF [70,
71]. One group considered mannitol in the perfusate as "indis-
pensable" [7] for the prevention of ischemic ARF in the graft.
Mannitol also protects the kidney against radiocontrast ne-
phropathy during heart catheterization in nondiabetic nonuremic
subjects [72]. However, under the same procedure mannitol may
aggravate radiocontrast nephrotoxicity in diabetic and in uremic
subjects [72, 73].
In an authoritative, exhaustive review on prophylactic interven-
tions in ARF, Conger [1] concedes that mannitol is of proven
usefulness in the management of post-transplant ARF. He could
not, however, document clear cut benefits of mannitol in the
prevention of clinical ARF outside the sphere of organ transplan-
tation.
Since mannitol ameliorates experimental myoglobinuric ARF
as well as ischemic ARF [74, 75] and since there has been partial
success with in the mannitol prevention of myoglobinuric ARF in
man [76], we decided to use this agent to supplement volume
replacement in casualties with the crush syndrome who were
referred to us from the Southern Lebanon front (1982-1983). That
front is less than 50 miles from our hospital in Haifa, so that we
could see casualties and start treatment early, following extrica-
tion from accidental burial under collapsed buildings.
During the search for survivors, when a limb was excavated an
iv. line was immediately secured, and lactated Ringer's solution
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Table 1. Actions of mannitol in the prophylaxis of post-traumatic acute
renal failure
Extrarenal
• Extracellular volume expansion with attendant increase in cardiac
output and stabilization of mean arterial pressure.
• Increased cardiac contractility [56, 57].
• Stimulation of atrial natriuretic factor release [24].
• Reduction of skeletal muscle cell edema and decompression of
muscle tamponade in the compartment syndrome [51, 52]. Possible
reduction of leakage of myoglobin and purine and phosphate from
injured muscles. Reduced filtered load of myoglobin urate, and
phosphate [83], all of which are nephrotoxic, indirectly protects the
kidneys.
• Restoration of normal tonus of the dilated blood vessels in crushed
muscles [80] and tilting the capillary Starling forces to favor of
extracellular fluid reabsorption.
Renal
• Decrease in blood viscosity and in oncotic pressure across the
glomerulus, causing an increase in glomerular filtration rate [16].
• Dilation of glomerular capillaries and stimulation of prostaglandin
E and I release [20].
• Increase in proximal intratubular urine flow and prevention of
obstruction [26, 74].
• Possible reduction of tubular cell swelling and injury [30, 31].
• Accelerated clearance of myoglobin, phosphate and urate from the
body [74].
• Scavenging of oxygen-free radicals [10, 11].
• Massive iv. dose of mannitol >200 glday have been reported to
cause acute renal [78, 79, 81] failure in rare cases. This type of
ARF is promptly reversible following hemodialysis [78, 84].
was infused at a rate of 1.5 liters/hr. It usually took between 4 to
8 hours to complete the extrication before the casualty was made
transportable to the hospital. Once urine flow started, further iv.
volume replacement was instituted at a rate of about 15 liters/day,
supplemented by mannitol (200 g/day 20% solution), and alkalin-
ization with bicarbonate.
With this regimen we were able to prevent myoglobinuric ARF
in casualties suffering from the crush syndrome who were trapped
under debris for 6 to 32 hours. Other casualties with the crush
syndrome of similar severity, to whom i.v. fluids could not be given
after more than six hours following release, all developed myo-
globinuric ARF [9].
The favorable effects of mannitol in casualties with the crush
syndrome may be due to its effect on the muscle as well as direct
renal effect. Thus, mannitol can decompress swollen muscles and
restore muscular contractility in experimental muscle crush injury
(Fig. 1, Table 1) [51, 52]. Such protective action of mannitol on
crushed skeletal muscles could conceivably reduce the sarcolem-
mal stretch and leak of myoglobin, purines and phosphate and
thus lower the burden of these nephrotoxic muscle metabolites on
the kidney. By increasing urinary clearance of myoglobin urate
and phosphate, mannitol may further accelerate the elimination
of extracellular pool of these metabolites. At the kidney level
mannitol is thought to decrease tubular cell swelling [30, 31], thus
increasing tubular flow and the dislodgment and flushing of
obstructive nephortoxic myoglobin casts. Hence the use of man-
niol in the management of the crush syndrome appears theoreti-
cally justified.
The relative importance of each component of our regimen for
the prevention of myoglobinuric ARF in humans (timing, rate of
infusion, solute and alkali content of i.v. fluids), cannot be
determined at present. In view of the favorable outcome of our iv.
Table 2. Mannitol nephrotoxicity
1. Occurs only following high dose of mannitol (>200 g/day)
2. Resembles vasomotor ARF
3. Prompt recovery following hemodialysis
4. Apparently associated with decompression of increased intracerebral
or intraocular pressure
Data are from Gadallah et al, Am J Med Sci 309:219—222, 1995 (case
report and review; N = 10). Used with permission.
strategy, however, we will continue to use it in the foreseeable
future, with the knowledge that some of its ingredients may be
redundant. Our regimen for the prevention of myoglobinuric
ARF has also been adopted by the ARF Task Force of the
International Society of Nephrology (Co-Chaired by N. Lemeire,
Ghent, Belgium and Kim Solez, Edmonton, Alberta, Canada. The
proceedings of the International Meeting on "Renal Aspects of
Disaster Relief," held May 1996 in Macedonia, is in Renal Failure,
in press).
ADVERSE REACTIONS TO MANNITOL
Rapid administration of mannitol causes expansion of the
extracellular fluid (ECF) and may in extreme cases precipitate
congestive heart failure or pulmonary edema particulary when
renal failure is established.
Administration of mannitol in dosage far in excess of 200 g/day
has on rare occasions produced ARF (Table 2) [77—79].
Most of these patients received mannitol to decompress in-
creased intra-cerebral or ocular pressures. Mannitol induced ARF
in humans appear to be of the vasomotor (renal constrictor) type
and responds promptly to removal of mannitol by hemodialysis
treatment [78, 791. It thus appears that whereas low doses of
mannitol have renal vasodilator effects, high doses of mannitol are
renal vasoconstrictor [21] to the point of precipitating ARF.
Furthermore, mannitol diuresis can increase renal energy de-
mands for Na reabsorption and so conceivably deplete ATP
stores, thus rendering the kidney susceptible to ARF.
It should be re-emphasized that severe clinical complications
following mannitol treatment occur rarely and only following
massive doses of mannitol 400 to 900 g/day [78, 80, 81].
In the late sixties there was some concern that the hypertonicity
of mannitol could damage erythrocytes. There is no clinical
evidence that such damage occurs in vivo, particularly if mannitol
solution is given iv. directly and not added to transfused blood.
Similarly, hyperkalemic effects of i.v. mannitol infusion have not
been reported to our best of knowledge.
Mannitol administration may aggravate radiocontrast nephrop-
athy in diabetic patients undergoing cardiac catheterization [72,
73].
Furthermore, 0.45% saline provided better protection against
radiocontrast nephropathy than mannitol in patients with chronic
renal failure [72, 73]. Thus, the use of mannitol for prephylaxis
against radiocontrast nephropathy is not recommended in pa-
tients with diabetes or chronic renal failure. Mannitol, however,
does offer protection against radiocontrast nephropathy in non-
diabetic nonuremic patients [72].
It should be noted that 11 of 20 patients with myoglobinuric
ARF of various etiologies were refractory to mannitol bicarbonate
infusion started from 24 to 28 hours after admission [76].
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Hyperkalemia caused by hypertonicity
An increase in plasma osmolarity, such as that caused by the
presence of mannitol in the plasma or hyperglycemia, may cause
a shift of water and potassium by solvent drag from the intracel-
lular to the extracellular space. We have observed such a shift in
humans when performing tests to assess the maximal tubular
capacity to reabsorb water, which was done by infusion of
hypertonic mannitol and antidiuretic hormone. The resulting
hyperkalemia was usually mild, and rarely exceeded 1.0 mEq/liter.
In clinical practice, one rarely encounters hyperkalemia during
hypertonic mannitol infusion, because the kaluretic properties of
mannitol apparently override the hyperkalemia caused by solvent
drag [82].
The paradox of "osmotic nephrosis" (reviewed by Gadalich and
Lynn, [781)
A large dose (2 to 4 g/kg body wt) of mannitol given to rabbits
causes swelling and vacuolization of proximal tubular cells. Sim-
ilar tubular changes were occasionally seen in renal biopsies from
patients undergoing mannitol diuresis. These structural tubular
changes were not apparently associated with impairment of renal
function. If mannitol is capable of causing tubular swelling in
normal kidneys, how does it protect against tubular epithelial
swelling in impending ARF [31]? There is no explanation at
present to reconcile this paradox. Furthermore, ARF following
excessive dosage of mannitol resembles vasomotor nephropathy
rather than toxic nephropathy.
NOTE ADDED IN PROOF
Reproduced with permission from DANIELS M, REICHMAN J, Ba±zis M:
Mannitol treatment for acute compartment syndrome. Nephron (in press)
Reprint requests to On S. Better, M.D., Faculty of Medicine, Technion,
POB 9649, Bat-Galim, Haifa 31096, IsraeL
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